Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.

Brannon AR, Frizziero M, Chen D, Hummel J, Gallo J, Riester M, Patel P, Cheung W, Morrissey M, Carbone C, Cottini S, Tortora G, Melisi D.

Cold Spring Harb Mol Case Stud. 2016 Mar;2(2):a000620. doi: 10.1101/mcs.a000620.

2.

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.

Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, Hsieh JJ.

Cancer Cell. 2016 Jan 11;29(1):104-16. doi: 10.1016/j.ccell.2015.12.004.

PMID:
26766592
3.

Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma.

Pulitzer MP, Brannon AR, Berger MF, Louis P, Scott SN, Jungbluth AA, Coit DG, Brownell I, Busam KJ.

Mod Pathol. 2015 Aug;28(8):1023-32. doi: 10.1038/modpathol.2015.60. Epub 2015 May 29.

4.

GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.

Tan MC, Basturk O, Brannon AR, Bhanot U, Scott SN, Bouvier N, LaFemina J, Jarnagin WR, Berger MF, Klimstra D, Allen PJ.

J Am Coll Surg. 2015 May;220(5):845-54.e1. doi: 10.1016/j.jamcollsurg.2014.11.029. Epub 2015 Feb 11.

5.

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O'Reilly C, Sadowska J, Casanova J, Yannes A, Hechtman JF, Yao J, Song W, Ross DS, Oultache A, Dogan S, Borsu L, Hameed M, Nafa K, Arcila ME, Ladanyi M, Berger MF.

J Mol Diagn. 2015 May;17(3):251-64. doi: 10.1016/j.jmoldx.2014.12.006. Epub 2015 Mar 20.

PMID:
25801821
6.

Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.

Shah RH, Scott SN, Brannon AR, Levine DA, Lin O, Berger MF.

Cancer Cytopathol. 2015 May;123(5):289-97. doi: 10.1002/cncy.21522. Epub 2015 Feb 5.

7.

Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.

Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK.

PLoS One. 2014 Dec 26;9(12):e116101. doi: 10.1371/journal.pone.0116101. eCollection 2014.

8.

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.

Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF.

Genome Biol. 2014 Aug 28;15(8):454. doi: 10.1186/s13059-014-0454-7.

9.

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner BH, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH, Solit DB, Taylor BS.

Cancer Discov. 2014 Sep;4(9):1014-21. doi: 10.1158/2159-8290.CD-14-0380. Epub 2014 Jun 16.

10.

Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.

Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, Russo P, Cheng EH, Motzer RJ, Berger MF, Hsieh JJ.

Clin Cancer Res. 2014 Apr 1;20(7):1955-64. doi: 10.1158/1078-0432.CCR-13-2345. Epub 2014 Mar 12.

11.

ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK.

Eur Urol. 2014 Jul;66(1):77-84. doi: 10.1016/j.eururo.2014.02.035. Epub 2014 Feb 25.

12.

Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.

Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, Fine SW, Gopalan A, Frizzell N, Voss MH, Russo P, Berger MF, Tickoo SK, Reuter VE.

Am J Surg Pathol. 2014 May;38(5):627-37. doi: 10.1097/PAS.0000000000000163.

13.

Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.

Won HH, Scott SN, Brannon AR, Shah RH, Berger MF.

J Vis Exp. 2013 Oct 18;(80):e50710. doi: 10.3791/50710.

14.

Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.

Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ.

Genome Res. 2014 Feb;24(2):241-50. doi: 10.1101/gr.158253.113. Epub 2013 Oct 24.

15.

"N of 1" case reports in the era of whole-genome sequencing.

Brannon AR, Sawyers CL.

J Clin Invest. 2013 Nov;123(11):4568-70. doi: 10.1172/JCI70935. Epub 2013 Oct 25.

16.

Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology.

Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK.

Eur Urol. 2012 Feb;61(2):258-68. doi: 10.1016/j.eururo.2011.10.007. Epub 2011 Oct 18.

17.

Basic research in kidney cancer.

Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A.

Eur Urol. 2011 Oct;60(4):622-33. doi: 10.1016/j.eururo.2011.06.048. Epub 2011 Jul 5. Review.

18.

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.

Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK.

Genes Cancer. 2010 Feb 1;1(2):152-163.

19.

Renal cell carcinoma: where will the state-of-the-art lead us?

Brannon AR, Rathmell WK.

Curr Oncol Rep. 2010 May;12(3):193-201. doi: 10.1007/s11912-010-0093-4. Review.

20.

Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.

Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV.

BMC Syst Biol. 2010 Apr 27;4:51. doi: 10.1186/1752-0509-4-51.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk